Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients

Next Previous
Trial Profile

A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CDX-3379 (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Pharmacodynamics
  • Sponsors Celldex Therapeutics Inc; Kolltan Pharmaceuticals

    • Most Recent Events

    • 03 Jan 2023 Results of pooled analysis of three studies (NCT00779389, NCT01218048, NCT02473731) assessing response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit, published in the Clinical Cancer Research.
    • 15 Jul 2019 Results published in the Clinical Cancer Research
    • 10 May 2018 Results presented in the Celldex Therapeutics Inc media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top